Exenatide (exendin-4) improves insulin sensitivity and {beta}-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight.

Gedulin BR, Nikoulina SE, Smith PA, Gedulin G, Nielsen LL, Baron AD, Parkes DG, Young AA

Endocrinology23 Dec 2004Cited by 178 (Europe PMC)

PMID15618356DOI10.1210/en.2004-1349PepBankPUB-15618356

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study15

11 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In obese Zucker rats, food intake was comparable between exenatide and pair-fed vehicle groups.
In plain wordsIn rats, food intake was similar with exenatide and pair-fed vehicle.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeFood intake
Study
Ratn: not reported in source
Nondiabetic insulin-resistant obese fa/fa Zucker rats
Comparator
Pair-fed vehicle control
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
Dose not stated · 6 weeksAs given in this study (Rat).
Source sentences
Summary
After 6 wk of treatment, ad libitum-fed exenatide-treated (EX) and pair-fed vehicle control (PF) rats had comparable food intake, body weight, hemoglobin A(1c) (HbA(1c)), and fasting plasma concentrations of glucose, insulin, and lipids.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of the incretin mimetic exenatide (exendin-4) on metabolic parameters, insulin sensitivity, and beta-cell mass were examined in nondiabetic, insulin-resistant obese fa/fa Zucker rats.
Report a problemFND-1561835601
02AnimalAnimal study (in vivo)Efficacy outcome
In obese Zucker rats, body weight was comparable between exenatide and pair-fed vehicle groups.
In plain wordsIn rats, body weight was similar with exenatide and pair-fed vehicle.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeBody weight
Study
Ratn: not reported in source
Nondiabetic insulin-resistant obese fa/fa Zucker rats
Comparator
Pair-fed vehicle control
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 6 weeksAs given in this study (Rat).
Source sentences
Summary
After 6 wk of treatment, ad libitum-fed exenatide-treated (EX) and pair-fed vehicle control (PF) rats had comparable food intake, body weight, hemoglobin A(1c) (HbA(1c)), and fasting plasma concentrations of glucose, insulin, and lipids.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of the incretin mimetic exenatide (exendin-4) on metabolic parameters, insulin sensitivity, and beta-cell mass were examined in nondiabetic, insulin-resistant obese fa/fa Zucker rats.
Report a problemFND-1561835602
03AnimalAnimal study (in vivo)Efficacy outcome
In obese Zucker rats, HbA1c was comparable between exenatide and pair-fed vehicle groups.
In plain wordsIn rats, HbA1c was similar with exenatide and pair-fed vehicle.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeHbA1c
Study
Ratn: not reported in source
Nondiabetic insulin-resistant obese fa/fa Zucker rats
Comparator
Pair-fed vehicle control
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 6 weeksAs given in this study (Rat).
Source sentences
Summary
After 6 wk of treatment, ad libitum-fed exenatide-treated (EX) and pair-fed vehicle control (PF) rats had comparable food intake, body weight, hemoglobin A(1c) (HbA(1c)), and fasting plasma concentrations of glucose, insulin, and lipids.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of the incretin mimetic exenatide (exendin-4) on metabolic parameters, insulin sensitivity, and beta-cell mass were examined in nondiabetic, insulin-resistant obese fa/fa Zucker rats.
Report a problemFND-1561835603
04AnimalAnimal study (in vivo)Efficacy outcome
In obese Zucker rats, fasting glucose was comparable between exenatide and pair-fed vehicle groups.
In plain wordsIn rats, fasting blood sugar was similar with exenatide and pair-fed vehicle.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeFasting glucose
Study
Ratn: not reported in source
Nondiabetic insulin-resistant obese fa/fa Zucker rats
Comparator
Pair-fed vehicle control
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 6 weeksAs given in this study (Rat).
Source sentences
Summary
After 6 wk of treatment, ad libitum-fed exenatide-treated (EX) and pair-fed vehicle control (PF) rats had comparable food intake, body weight, hemoglobin A(1c) (HbA(1c)), and fasting plasma concentrations of glucose, insulin, and lipids.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of the incretin mimetic exenatide (exendin-4) on metabolic parameters, insulin sensitivity, and beta-cell mass were examined in nondiabetic, insulin-resistant obese fa/fa Zucker rats.
Report a problemFND-1561835604
05AnimalAnimal study (in vivo)Efficacy outcome
In obese Zucker rats, fasting insulin was comparable between exenatide and pair-fed vehicle groups.
In plain wordsIn rats, fasting insulin was similar with exenatide and pair-fed vehicle.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeFasting insulin
Study
Ratn: not reported in source
Nondiabetic insulin-resistant obese fa/fa Zucker rats
Comparator
Pair-fed vehicle control
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 6 weeksAs given in this study (Rat).
Source sentences
Summary
After 6 wk of treatment, ad libitum-fed exenatide-treated (EX) and pair-fed vehicle control (PF) rats had comparable food intake, body weight, hemoglobin A(1c) (HbA(1c)), and fasting plasma concentrations of glucose, insulin, and lipids.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of the incretin mimetic exenatide (exendin-4) on metabolic parameters, insulin sensitivity, and beta-cell mass were examined in nondiabetic, insulin-resistant obese fa/fa Zucker rats.
Report a problemFND-1561835605
06AnimalAnimal study (in vivo)Efficacy outcome
In obese Zucker rats, fasting plasma lipids were comparable between exenatide and pair-fed vehicle groups.
In plain wordsIn rats, fasting blood fats were similar with exenatide and pair-fed vehicle.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeFasting lipids
Study
Ratn: not reported in source
Nondiabetic insulin-resistant obese fa/fa Zucker rats
Comparator
Pair-fed vehicle control
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated · 6 weeksAs given in this study (Rat).
Source sentences
Summary
After 6 wk of treatment, ad libitum-fed exenatide-treated (EX) and pair-fed vehicle control (PF) rats had comparable food intake, body weight, hemoglobin A(1c) (HbA(1c)), and fasting plasma concentrations of glucose, insulin, and lipids.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of the incretin mimetic exenatide (exendin-4) on metabolic parameters, insulin sensitivity, and beta-cell mass were examined in nondiabetic, insulin-resistant obese fa/fa Zucker rats.
Report a problemFND-1561835606
07AnimalAnimal study (in vivo)Efficacy outcome
In obese Zucker rats, insulin sensitivity index was 224% higher with exenatide than ad libitum-fed vehicle control.
In plain wordsIn rats, insulin sensitivity was 224% higher with exenatide than vehicle controls allowed to eat freely.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseInsulin sensitivity index versus ad libitum control
Study
Ratn: not reported in source
Nondiabetic insulin-resistant obese fa/fa Zucker rats
Comparator
Ad libitum-fed vehicle control
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 6 weeksAs given in this study (Rat).
Measurements
Insulin sensitivity index difference
224%
exenatide versus ad libitum vehicle
Source sentences
Summary
The insulin sensitivity index (ISI; glucose infusion rate to plasma insulin concentration) measured during a hyperinsulinemic euglycemic clamp was 224% higher in EX rats than CON rats (P < 0.001) and 61% higher in EX rats than PF rats (P < 0.004).
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of the incretin mimetic exenatide (exendin-4) on metabolic parameters, insulin sensitivity, and beta-cell mass were examined in nondiabetic, insulin-resistant obese fa/fa Zucker rats.
Report a problemFND-1561835611
08AnimalAnimal study (in vivo)Efficacy outcome
In obese Zucker rats, insulin sensitivity index was 61% higher with exenatide than pair-fed vehicle control.
In plain wordsIn rats, insulin sensitivity was 61% higher with exenatide than pair-fed vehicle.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseInsulin sensitivity index versus pair-fed control
Study
Ratn: not reported in source
Nondiabetic insulin-resistant obese fa/fa Zucker rats
Comparator
Pair-fed vehicle control
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 6 weeksAs given in this study (Rat).
Measurements
Insulin sensitivity index difference
61%
exenatide versus pair-fed vehicle
Source sentences
Summary
The insulin sensitivity index (ISI; glucose infusion rate to plasma insulin concentration) measured during a hyperinsulinemic euglycemic clamp was 224% higher in EX rats than CON rats (P < 0.001) and 61% higher in EX rats than PF rats (P < 0.004).
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of the incretin mimetic exenatide (exendin-4) on metabolic parameters, insulin sensitivity, and beta-cell mass were examined in nondiabetic, insulin-resistant obese fa/fa Zucker rats.
Report a problemFND-1561835612
09AnimalAnimal study (in vivo)Efficacy outcome
In obese Zucker rats, total cholesterol was comparable between exenatide and pair-fed vehicle groups.
In plain wordsIn rats, total cholesterol was similar with exenatide and pair-fed vehicle.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeTotal cholesterol
Study
Ratn: not reported in source
Nondiabetic insulin-resistant obese fa/fa Zucker rats
Comparator
Pair-fed vehicle control
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated · 6 weeksAs given in this study (Rat).
Source sentences
Summary
The latter difference was despite comparable HbA(1c), fasting glucose, fasting insulin, total cholesterol, high-density lipoprotein, and daily food consumption between EX and PF animals.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of the incretin mimetic exenatide (exendin-4) on metabolic parameters, insulin sensitivity, and beta-cell mass were examined in nondiabetic, insulin-resistant obese fa/fa Zucker rats.
Report a problemFND-1561835613
10AnimalAnimal study (in vivo)Efficacy outcome
In obese Zucker rats, high-density lipoprotein was comparable between exenatide and pair-fed vehicle groups.
In plain wordsIn rats, high-density lipoprotein was similar with exenatide and pair-fed vehicle.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeHigh-density lipoprotein
Study
Ratn: not reported in source
Nondiabetic insulin-resistant obese fa/fa Zucker rats
Comparator
Pair-fed vehicle control
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated · 6 weeksAs given in this study (Rat).
Source sentences
Summary
The latter difference was despite comparable HbA(1c), fasting glucose, fasting insulin, total cholesterol, high-density lipoprotein, and daily food consumption between EX and PF animals.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of the incretin mimetic exenatide (exendin-4) on metabolic parameters, insulin sensitivity, and beta-cell mass were examined in nondiabetic, insulin-resistant obese fa/fa Zucker rats.
Report a problemFND-1561835614
11AnimalAnimal study (in vivo)Efficacy outcome
In obese Zucker rats, the beta-cell mass times insulin sensitivity product was 63% greater with exenatide than pair-fed vehicle.
In plain wordsIn rats, beta-cell mass times insulin sensitivity was 63% greater with exenatide than pair-fed vehicle.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseBeta-cell mass times insulin sensitivity index
Study
Ratn: not reported in source
Nondiabetic insulin-resistant obese fa/fa Zucker rats
Comparator
Pair-fed vehicle control
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 6 weeksAs given in this study (Rat).
Measurements
Beta-cell mass times ISI difference
63%
exenatide versus pair-fed vehicle
Source sentences
Summary
Analogous to the disposition index, the beta-cell mass * ISI product was 63% greater in EX than PF rats (P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of the incretin mimetic exenatide (exendin-4) on metabolic parameters, insulin sensitivity, and beta-cell mass were examined in nondiabetic, insulin-resistant obese fa/fa Zucker rats.
Report a problemFND-1561835615

Studies that did not test the peptide alone4

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

12AnimalNot a test of Exenatide (exendin-4) aloneAnimal study (in vivo)Efficacy outcome
In obese Zucker rats, food intake decreased in both exenatide-treated and pair-fed vehicle groups versus ad libitum-fed vehicle controls.
In plain wordsIn rats, food intake decreased in both exenatide-treated and pair-fed vehicle groups versus vehicle controls allowed unrestricted food.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseFood intake versus ad libitum control
Study
Ratn: not reported in source
Nondiabetic insulin-resistant obese fa/fa Zucker rats
Comparator
Ad libitum-fed vehicle control
Outcome group
Appetite and food intake · Metabolic and weight
Source sentences
Summary
Concurrent decreases in food intake and weight gain were observed in EX and PF rats, compared with ad libitum-fed vehicle control (CON) rats (P < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of the incretin mimetic exenatide (exendin-4) on metabolic parameters, insulin sensitivity, and beta-cell mass were examined in nondiabetic, insulin-resistant obese fa/fa Zucker rats.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-1561835607
13AnimalNot a test of Exenatide (exendin-4) aloneAnimal study (in vivo)Efficacy outcome
In obese Zucker rats, weight gain decreased in both exenatide-treated and pair-fed vehicle groups versus ad libitum-fed vehicle controls.
In plain wordsIn rats, weight gain decreased in both exenatide-treated and pair-fed vehicle groups versus vehicle controls allowed unrestricted food.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseWeight gain versus ad libitum control
Study
Ratn: not reported in source
Nondiabetic insulin-resistant obese fa/fa Zucker rats
Comparator
Ad libitum-fed vehicle control
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Concurrent decreases in food intake and weight gain were observed in EX and PF rats, compared with ad libitum-fed vehicle control (CON) rats (P < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of the incretin mimetic exenatide (exendin-4) on metabolic parameters, insulin sensitivity, and beta-cell mass were examined in nondiabetic, insulin-resistant obese fa/fa Zucker rats.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-1561835608
14AnimalNot a test of Exenatide (exendin-4) aloneAnimal study (in vivo)Efficacy outcome
In obese Zucker rats, the disease-related rise in HbA1c decreased in both exenatide-treated and pair-fed vehicle groups versus ad libitum-fed vehicle controls.
In plain wordsIn rats, HbA1c progression decreased in both exenatide-treated and pair-fed vehicle groups versus vehicle controls allowed unrestricted food.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseHbA1c progression
Study
Ratn: not reported in source
Nondiabetic insulin-resistant obese fa/fa Zucker rats
Comparator
Ad libitum-fed vehicle control
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
The increases in HbA(1c) and fasting plasma insulin concentrations that occur during the normal progression of this disease model were significantly reduced in EX and PF rats, compared with CON rats (P < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of the incretin mimetic exenatide (exendin-4) on metabolic parameters, insulin sensitivity, and beta-cell mass were examined in nondiabetic, insulin-resistant obese fa/fa Zucker rats.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-1561835609
15AnimalNot a test of Exenatide (exendin-4) aloneAnimal study (in vivo)Efficacy outcome
In obese Zucker rats, the disease-related rise in fasting insulin decreased in both exenatide-treated and pair-fed vehicle groups versus ad libitum-fed vehicle controls.
In plain wordsIn rats, fasting insulin progression decreased in both exenatide-treated and pair-fed vehicle groups versus vehicle controls allowed unrestricted food.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseFasting insulin progression
Study
Ratn: not reported in source
Nondiabetic insulin-resistant obese fa/fa Zucker rats
Comparator
Ad libitum-fed vehicle control
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
The increases in HbA(1c) and fasting plasma insulin concentrations that occur during the normal progression of this disease model were significantly reduced in EX and PF rats, compared with CON rats (P < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of the incretin mimetic exenatide (exendin-4) on metabolic parameters, insulin sensitivity, and beta-cell mass were examined in nondiabetic, insulin-resistant obese fa/fa Zucker rats.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-1561835610

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.